# Development of a supportive mHealth device for persons with schizophrenia spectrum disorders (KisoLightApp): a usability study within a participant-involvement principle

## TL;DR

A new mobile app called KisoLightApp was tested for people with schizophrenia spectrum disorders and found to be safe, usable, and satisfying.

## Contribution

The study introduces and evaluates a novel mHealth app designed specifically for individuals with schizophrenia spectrum disorders.

## Key findings

- Most participants used the app regularly, indicating good engagement.
- The app was found to be highly usable and satisfactory with no serious adverse events.
- Future research should test an improved version in a larger randomized controlled trial.

## Abstract

To address the severe treatment gap in persons with schizophrenia spectrum disorders (SSD), this study aims to examine the usability of and satisfaction with a novel and initial mHealth application (KisoLightApp) for SSD in Germany. The app is designed as a stand-alone tool that offers specific features such as symptom monitoring, medication adherence, and activity planning.

Within a single-arm usability trial, N = 19 participants engaged with the app over 2 weeks and completed baseline and post-engagement assessments. Quantitative and qualitative measures were included to assess feedback for the continuous development of the KisoApp.

The majority of participants engaged with the app regularly (n = 17 [89.50%], multiple times per week or daily). Descriptive results indicate a high usability and satisfaction with the app. Although a few unserious unwanted events (UEs) were reported, there were no serious UEs or adverse treatment reactions (ATR), indicating the safety of the app.

The KisoLightApp for persons with SSD seem to be a safe, usable, and satisfying tool for supporting the addressed population. Future studies should examine an enhanced version of the app within a randomized controlled trial, including a larger sample size and additional therapeutic features.